T1	Intervention 26 44	placebo-controlled
T2	Intervention 109 122	dexamethasone
T3	Intervention 136 167	following adjuvant chemotherapy
T4	Intervention 289 316	after adjuvant chemotherapy
T5	Intervention 350 371	receive dexamethasone
T6	Intervention 471 493	receiving chemotherapy
T7	Intervention 529 558	with dexamethasone or placebo
T8	Intervention 741 759	oral dexamethasone
T9	Intervention 792 806	versus placebo
T10	Intervention 882 940	intravenous granisetron and dexamethasone pre-chemotherapy
T11	Intervention 945 961	oral granisetron
T12	Intervention 1145 1194	received fluorouracil/epirubicin/cyclophosphamide
T13	Intervention 1202 1239	received doxorubicin/cyclophosphamide
T14	Intervention 1345 1362	preferred placebo
T15	Intervention 1416 1450	35-58Â %) preferred dexamethasone;
T16	Intervention 1622 1653	patients received dexamethasone
T17	Intervention 1799 1834	regardless of whether dexamethasone
T18	Intervention 1846 1869	was used after adjuvant
